Testing a New Brain Imaging Agent for Neurodegenerative Diseases

Plain-English translation of NCT05395624 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

Researchers are testing a new imaging agent called that can help detect inflammation in the brain caused by immune cell activation. This medication is given as an injection, and then a PET imaging scan allows doctors to see where brain inflammation is happening. The study aims to see if this approach can help identify disease earlier and track how well future treatments work.

Several neurodegenerative diseases like ALS, Alzheimer's, MS, and Parkinson's involve brain inflammation, but current imaging methods are not very precise at detecting it. This trial exists to test whether this new medication can give doctors a better, earlier way to see brain inflammation and measure how well anti-inflammatory treatments are working.

Do you qualify?

You likely qualify if…

you are able to understand and sign the study consent form
you are between 18 and 80 years old (or 40 to 80 if you have Alzheimer's disease)
you have a clinical diagnosis of ALS, Alzheimer's disease, multiple sclerosis, Parkinson's disease, or are a healthy volunteer
you have normal kidney function as measured by a blood test
if you are a woman of childbearing age, you agree to use effective birth control during the study and for 6 months after

You likely don't qualify if…

you are pregnant, breastfeeding, or planning to become pregnant
you have kidney disease or significantly reduced kidney function
you have high levels of inflammation markers (C-reactive protein) in your blood
you are unable to remain still for imaging scans lasting up to 90 minutes

What participation looks like

You will receive a single injection of the imaging agent and then undergo a PET scan, which takes about 90 minutes. You may need to visit the research clinic multiple times for screening blood tests, kidney function checks, and pregnancy tests (if applicable). The study involves minimal time commitment beyond the imaging visit, and you will receive clear instructions about what to expect during the scan and any preparation needed beforehand.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(3 sites)

United States

UCSF, San Francisco, California

Stanford University, Stanford, California

Mayo Clinic Jacksonville, Jacksonville, Florida